Arca
Skip to content
Tools
Tools

Pericarditis

Drug research and approvals for pericarditis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 14 studies of pericarditis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 14
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 14 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 5

Phase 2 1

  • CannabidiolCannabinoid CB1 receptor negative allosteric modulator

How its trials ended

46 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 14 whose ending is known, 50% met their primary endpoint, 7% missed it and 43% stopped early.

  • Ongoing1839%
  • Completed, result not reported817%
  • Met its primary endpoint715%
  • Status unknown613%
  • Stopped: other or unclear511%
  • Missed its primary endpoint12%
  • Stopped: enrollment or feasibility12%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 14, 2025A phase 2a, open-label pilot study to evaluate the safety/tolerability, efficacy, pharmacokinetics, and pharmacodynamics of VTX2735 in participants with…LY5625574 (VTX2735)Zomagen Biosciences Ltd.Ongoing
Nov 7, 2025A phase 2 posology study with long-term extension in participants with well controlled recurrent pericarditis to evaluate the efficacy and safety of transition…KPL-387 (antithrombin concentrate)Kiniksa Pharmaceuticals (UK)Ongoing
Jul 23, 2025A phase 2/3 efficacy and safety study of KPL-387 treatment in participants with recurent pericarditisKPL-387Kiniksa Pharmaceuticals (UK)Pending
Feb 27, 2025Identifying clinical, serum, and imaging based biomarkers associated with high-risk phenotypes for recurrent pericarditis: a prospective cohort study18F-fluorodeoxyglucose (18F-FDG)Ottawa Heart Institute Research CorporationOngoing
Nov 19, 2024Impact of cardiolrx over 6 months following IL-1 blocker cessation in pericarditis patients - maveric-2. a randomized, double-blind, placebo-controlled trialCannabidiol (cardiolrx)Cardiol Therapeutics IncOngoing

FDA orphan designations

Approved first, then open designations, newest first
Mar 18, 2021ArcalystTreatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and olderKiniksa Pharmaceuticals, Ltd.Approved
Feb 13, 2026Peripherally restricted, selective, small molecule…Treatment of pericarditisZomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences, Ltd.Designated
Dec 31, 2025ColchicineTreatment of pericarditisPharmascience Inc.Designated
Oct 16, 2025Fully human IgG2 monoclonal antibody that blocks…Treatment of pericarditisKiniksa Pharmaceuticals,GmbH,c/o Kiniksa Pharmaceuticals CorpDesignated
Apr 16, 2025ColchicineTreatment of pericarditisScilex Pharmaceuticals Inc.Designated
Oct 11, 2024GoflikiceptTreatment of pericarditisR-Pharm Overseas, Inc.Designated
Oct 9, 2024ColchicineTreatment of pericarditisACARPIA Farmaceutici S.r.l.Designated
Feb 14, 2024CannabidiolTreatment of pericarditis.Cardiol Therapeutics Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.